Slide 1: Biotron Limited (ASX:BIT) October 2023
BIOTRON LIMITED (ASX:BIT) October 2023
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation may contain forward‐looking statements with respect to the financial condition, results and business achievements/performance of Biotron Limited (ACN 086 399 144) and certain of the plans and objectives of its management. These statements are statements t
Slide 3: Industry-leading experts focused on transformative treatments for viral diseases
Industry-leading experts focused on transformative treatments for viral diseases • Experienced Board and management team with pharma, financial and VC backgrounds • Clinical stage company with portfolio of small molecule drugs targeting viral diseases with major health problems and large internation
Slide 4: Near-term value creation milestones anticipated in late 2023
Near-term value creation milestones anticipated in late 2023 • The headline results from three human Phase 2 clinical trials are expected in coming weeks • Two HIV-1 Phase 2 trials and a SARS-CoV-2/COVID-19 Phase 2 trial • All three trials have been completed i.e. all patients have been recruited an
Slide 5: Financial Information
Financial Information Key Financial Metrics Ticker Code ASX: BIT Share Price (19/10/2023) A $0.088 Market Cap A $77 million 12 Month Trading Range A $0.024 – 0.115 BITOC 25/11/24 $0.06 listed options A $0.055 (19 Oct) Cash Position (06/2023) A $3.98 million Top 20 shareholders 18.87% Board Michael H
Slide 6: Portfolio of Clinical and Preclinical Assets
Portfolio of Clinical and Preclinical Assets RESEARCH DEVELOPMENT DISCOVERY/LEAD INDICATION COMPOUND IND ENABLING/ PRECLINICAL PHASE 1 PHASE 2 PHASE 3 OPTIMISATION HIV-1 BIT225 * HIV-1 Next generation COVID-19 BIT225 * COVID-19 Next generation HBV Lead Optimisation Dengue, Influenza, and Leads other
Slide 7: Recent Milestones & Achievements
Recent Milestones & Achievements • Completed enrolment of two Phase 2 HIV-1 clinical trials that build on positive results in previous clinical studies • Completed enrolment of Phase 2 COVID-19 clinical trial • Based on demonstration that BIT225 prevents development of COVID-19 disease in an industr
Slide 8: COVID-19 Clinical Program
COVID-19 Clinical Program • In 2022 Biotron’s lead antiviral drug BIT225 was shown to: WHY COVID? • Prevent COVID-19, • Some vulnerable populations remain at risk • Reduce virus levels, and • Current drugs have limitations due to • Stop the cytokine storm in a relevant, robust, industry-recognised d
Slide 9: BIT225 Prevents COVID-19 in Animal Model of Disease
BIT225 Prevents COVID-19 in Animal Model of Disease Twelve-day treatment of SARS-CoV-2 infected K18-hACE2 mice with BIT225. (A) Dosing Scheme. (B) Kaplan-Meier plot: vehicle control (black line, n = 7, 0% survival); BIT225 12-day treatment group (blue line, n = 7, 100% survival). (C) Body weight cha
Slide 10: HIV-1 Clinical Program
HIV-1 Clinical Program Why HIV-1? • Two Phase 2 HIV-1 clinical trials recently completed at sites in Sydney, Australia • Despite antiretroviral drugs (ART) over 38.4 million people (Holdsworth House, East Sydney Doctors and St Vincent’s Hospital, Darlinghurst) globally are living with HIV and in Tha
Slide 11: Unlocking value for other viral targets
Unlocking value for other viral targets • Post pandemic there is an international focus on preparedness for future viral outbreaks • Small molecule drugs are essential to beating the next pandemic • The threat of emerging pandemics is real, especially for coronavirus and other high-risk respiratory
Slide 12: BIT225 Opportunity Summary
BIT225 Opportunity Summary • BIT225 is a very important clinical asset for Biotron • Previous positive clinical trial data have significantly de-risked the program • Clear clinical development program designed to demonstrate to regulators and pharma how the drug may be used to improve health outcome
Slide 13: Biotron Limited (ASX:BIT)
BIOTRON LIMITED (ASX:BIT) Michelle Miller Managing Director mmiller@biotron.com.au www.biotron.com.au +61 412313329